Background Predictors of COVID-19 vaccine immunogenicity and the influence of prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection require elucidation.Methods Stop the Spread Ottawa is a prospective cohort of individuals at-risk for or who have been infected with SARS-CoV-2, initially enrolled for 10 months beginning October 2020. This cohort was enriched for public-facing workers. This analysis focuses on safety and immunogenicity of the initial two doses of COVID-19 vaccine.Results Post-vaccination data with blood specimens were available for 930 participants. 22.8% were SARS-CoV2 infected prior to the first vaccine dose. Cohort characteristics include: median age 44 (IQR: 22–56), 66.6% women, 89.0% white, 83.2% em...
Objectives: To assess total antibody levels against Severe Acute Respiratory Syndrome CoronaVirus 2 ...
The global supply of COVID-19 vaccines remains limited. An understanding of the immune response that...
Background: SARS-CoV-2 vaccines are an invaluable resource against COVID-19. Current vaccine shortag...
Background: Vaccine mediated SARS-CoV-2 antibody responses should be carefully evaluated. With regul...
International audienceBackground: Assessment of the kinetics of SARS-CoV-2 antibodies is essential i...
BackgroundWe evaluated measures to protect healthcare workers (HCWs) in Vancouver, Canada, where var...
Summary: Background: Immunocompromised patients have varying responses to SARS-CoV-2 mRNA vaccinati...
Objective To compare outcomes between O and non-O blood groups, and by modified RNA (mRNA) and adeno...
INTRODUCTION: In the context of recurrent surges of SARS-CoV-2 infections, a detailed characterizati...
Background: Immunocompromised patients have varying responses to SARS-CoV-2 mRNA vaccination. Howeve...
It is well-known that the Coronavirus Disease 2019, which is caused by the beta-coronavirus severe a...
Background: Recent reports have suggested that among individuals previously infected with SARS-CoV-2...
Background: Heterogeneity of the population in relation to infection, COVID-19 vaccination, and host...
To assess vaccine immunogenicity in non-infected and previously infected individuals in a real-world...
Background: Monitoring the longevity of immunoglobulin G (IgG) responses following severe acute resp...
Objectives: To assess total antibody levels against Severe Acute Respiratory Syndrome CoronaVirus 2 ...
The global supply of COVID-19 vaccines remains limited. An understanding of the immune response that...
Background: SARS-CoV-2 vaccines are an invaluable resource against COVID-19. Current vaccine shortag...
Background: Vaccine mediated SARS-CoV-2 antibody responses should be carefully evaluated. With regul...
International audienceBackground: Assessment of the kinetics of SARS-CoV-2 antibodies is essential i...
BackgroundWe evaluated measures to protect healthcare workers (HCWs) in Vancouver, Canada, where var...
Summary: Background: Immunocompromised patients have varying responses to SARS-CoV-2 mRNA vaccinati...
Objective To compare outcomes between O and non-O blood groups, and by modified RNA (mRNA) and adeno...
INTRODUCTION: In the context of recurrent surges of SARS-CoV-2 infections, a detailed characterizati...
Background: Immunocompromised patients have varying responses to SARS-CoV-2 mRNA vaccination. Howeve...
It is well-known that the Coronavirus Disease 2019, which is caused by the beta-coronavirus severe a...
Background: Recent reports have suggested that among individuals previously infected with SARS-CoV-2...
Background: Heterogeneity of the population in relation to infection, COVID-19 vaccination, and host...
To assess vaccine immunogenicity in non-infected and previously infected individuals in a real-world...
Background: Monitoring the longevity of immunoglobulin G (IgG) responses following severe acute resp...
Objectives: To assess total antibody levels against Severe Acute Respiratory Syndrome CoronaVirus 2 ...
The global supply of COVID-19 vaccines remains limited. An understanding of the immune response that...
Background: SARS-CoV-2 vaccines are an invaluable resource against COVID-19. Current vaccine shortag...